[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  quantumup [@Quantumup1](/creator/twitter/Quantumup1) on x 3534 followers Created: 2025-07-21 17:37:06 UTC H.C. Wainwright reiterated $CRNX Buy-$81 and said, "At the #ENDO 2025 conference, we felt strong enthusiasm towards Palsonify (paltusotine) from many expert endocrinologists." $BCHMY $IPSEY $NVS #ENDO2025 H.C. Wainwright added, "They were all excited about the drug's compelling efficacy and durability on top of a convenient once-daily dosing regimen. Many called it a "game changer" in acromegaly compared to the current standard-of-care, whether intramuscular somatostatin receptor ligands (SRL) injections or twice-daily oral SRLs. Unlike the injectables, paltusotine has been shown to provide consistent biochemical and symptom control and reduce breakthrough symptoms. Its once-daily dosing allows patients to take it at bedtime without having to worry about fasting and food effects that are challenges with the twice-daily oral SRLs. The endocrinologists we spoke to all expected most of their acromegaly patients to switch to paltusotine. We reiterate our Buy and our price target of $XX for Crinetics." XXXXX engagements  **Related Topics** [ole](/topic/ole) [longterm](/topic/longterm) [drugs](/topic/drugs) [$nvs](/topic/$nvs) [$ipsey](/topic/$ipsey) [$bchmy](/topic/$bchmy) [$crnx](/topic/$crnx) [Post Link](https://x.com/Quantumup1/status/1947350133655396445)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
quantumup @Quantumup1 on x 3534 followers
Created: 2025-07-21 17:37:06 UTC
H.C. Wainwright reiterated $CRNX Buy-$81 and said, "At the #ENDO 2025 conference, we felt strong enthusiasm towards Palsonify (paltusotine) from many expert endocrinologists." $BCHMY $IPSEY $NVS #ENDO2025 H.C. Wainwright added, "They were all excited about the drug's compelling efficacy and durability on top of a convenient once-daily dosing regimen.
Many called it a "game changer" in acromegaly compared to the current standard-of-care, whether intramuscular somatostatin receptor ligands (SRL) injections or twice-daily oral SRLs.
Unlike the injectables, paltusotine has been shown to provide consistent biochemical and symptom control and reduce breakthrough symptoms. Its once-daily dosing allows patients to take it at bedtime without having to worry about fasting and food effects that are challenges with the twice-daily oral SRLs.
The endocrinologists we spoke to all expected most of their acromegaly patients to switch to paltusotine. We reiterate our Buy and our price target of $XX for Crinetics."
XXXXX engagements
